MDACC Study No:2012-1040(2012-0137CLL) ( NCT No: NCT01476657)
Title:A Phase I Study of IPI-145 in Patients with Advanced Hematologic Malignancies
Principal Investigator:Nitin Jain
Treatment Agent:IPI-145
Study Status:Closed
Study Description:The goal of this clinical research study is to learn about the safety of
IPI-145 and find the highest tolerable dose that can be given to patients with
advanced blood cancer.

IPI-145 is designed to block the normal signals in blood cells that tell the
cells to divide and grow. This may cause cancer cells to stop growing and/or
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:IPI-145
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Infinity Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nitin Jain
For Clinical Trial Enrollment:713-745-6080
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults